Nectar Lifesciences Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company generates healthy free cash flow
CONS
- Company is loss-making at the operating / net level
- Operating cash flow has been negative in recent years
- Company has a low return on equity of -2.3% over last 3 years
- Company has a low return on capital employed of 0.7%
- Interest coverage is weak at -1.3x - earnings barely cover interest
- Promoter holding has decreased over last 2 years: -4.0pp
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| NECLIFE | 12.22 | 14.27 | 237.39 | 0.00 | -15.40 | 75.65 | 0.44 | -99.84 | -4.75 | -6170.14 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 394 | 398 | 452 | 440 | 359 | 6 | 0 | 0 | 281 | 5 | 0 | 0 | 0 | |
| 359 | 371 | 410 | 393 | 320 | 6 | 0 | 0 | 343 | 6 | 2 | 59 | 28 | |
| Operating Profit | 36 | 27 | 42 | 47 | 39 | -1 | -0 | -0 | -62 | -1 | -2 | -59 | -28 |
| OPM % | 9.02% | 6.75% | 9.33% | 10.68% | 10.97% | -10.30% | — | — | -22.05% | -20.80% | — | — | -6230.77% |
| 0 | 11 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 89 | 6 | 3 | |
| Interest | 18 | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 19 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 |
| Profit before Tax | 3 | 2 | 2 | 11 | 5 | -0 | 0 | -0 | -97 | -1 | 57 | -57 | -25 |
| Tax % | 40.52% | 38.41% | 36.33% | 94.69% | 39.63% | 34.29% | 34.29% | 37.50% | 34.64% | 35.29% | -19.49% | 34.64% | 36.15% |
| Net Profit | 0 | 0 | 0 | 0 | 3 | 56 | 78 | -1,301 | -63 | -1,760 | 143 | -679 | -15 |
| 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | -0.01 | 0.01 | -5.80 | -2.82 | -0.01 | 3.02 | -3.38 | -0.79 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,644 | 1,876 | 2,783 | 2,366 | 1,543 | 1,669 | 1,524 | 1,684 | 0 | 0 | 5 | |
| 1,419 | 1,640 | 2,519 | 2,147 | 1,442 | 1,510 | 1,471 | 1,533 | 0 | 61 | 94 | |
| Operating Profit | 224 | 236 | 264 | 220 | 101 | 159 | 53 | 152 | -0 | -61 | -89 |
| OPM % | 13.65% | 12.59% | 9.49% | 9.28% | 6.57% | 9.50% | 3.48% | 9.00% | — | — | -1636.16% |
| 23 | 6 | 6 | 4 | -14 | 11 | 53 | 17 | 10 | 11 | 98 | |
| Interest | 117 | 115 | 148 | 126 | 112 | 79 | 89 | 90 | 9 | 37 | 36 |
| Depreciation | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 1 | 0 | 0 |
| Profit before Tax | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | 1 | -88 | -25 |
| Tax % | 17.92% | 16.61% | 19.08% | 15.16% | 13.57% | 26.51% | 42.99% | 72.66% | 34.98% | 34.74% | 156.45% |
| Net Profit | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | 1 | -57 | 14 |
| EPS | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 | — |
| Dividend Payout % | 2.03% | 2.10% | 2.34% | 3.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -10%
- 5 Years:
- -16%
- 3 Years:
- -24%
- 1 Year:
- -17%
RETURN ON EQUITY
- 10 Years:
- 0%
- 5 Years:
- -1%
- 3 Years:
- -2%
- Last Year:
- -7%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
| 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 | |
| 897 | 973 | 916 | 781 | 906 | 795 | 755 | 553 | 501 | 9 | |
| Trade Payables | 528 | 539 | 484 | 527 | 342 | 377 | 319 | 420 | 438 | 0 |
| 149 | 153 | 201 | 189 | 66 | 128 | 31 | 141 | 97 | -194 | |
| Total Liabilities | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,169 | 2,184 | 1,992 | 397 |
| 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 | |
| Capital Work in Progress | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 | |
| 855 | 859 | 918 | 978 | 588 | 660 | 673 | 709 | 690 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 379 | 345 | 0 | |
| Cash & Bank | 13 | 9 | 21 | 21 | 26 | 18 | 18 | 20 | 19 | 112 |
| 729 | 902 | 841 | 734 | 891 | 901 | 738 | 366 | 247 | 167 | |
| Total Assets | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,169 | 2,184 | 1,992 | 397 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 206 | 78 | 253 | 294 | 25 | 95 | 134 | 225 | 169 | -349 | |
| Cash from Investing | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Cash from Financing | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -767 |
| -23 | -4 | 12 | -0 | 4 | -8 | -0 | 2 | -1 | 93 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | 2.47 | 2.38 | 2.13 | 1.44 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 |
| Book Value (₹) | 44.89 | 47.21 | 49.28 | 50.66 | 47.36 | 48.51 | 47.47 | 47.68 | 42.63 | 29.98 |
| Dividend per Share (₹) | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 5.24 | 5.20 | 4.94 | 4.13 | -0.58 | 3.66 | 1.56 | 2.93 | 0.06 | -2.93 |
| PROFITABILITY | ||||||||||
| Operating Margin % | 14.17% | 11.57% | 8.68% | 8.48% | 6.40% | 8.82% | 6.07% | 7.87% | 0.00% | 0.00% |
| Net Margin % | 3.17% | 2.50% | 1.53% | 1.20% | -4.15% | 1.30% | -1.38% | 0.26% | 0.00% | 0.00% |
| ROE % | 5.64% | 5.06% | 4.40% | 2.84% | -6.67% | 2.33% | -2.25% | 0.47% | 0.07% | -7.46% |
| ROCE % | 9.73% | 9.13% | 10.29% | 8.32% | 1.41% | 5.77% | 2.49% | 6.12% | 0.59% | -4.75% |
| 2.15% | 1.97% | 1.75% | 1.19% | -2.93% | 1.05% | -1.06% | 0.23% | 0.03% | -4.80% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 104 | 97 | 69 | 66 | 80 | 78 | 76 | 62 | 0 | 0 |
| Inventory Days | 177 | 149 | 104 | 131 | 162 | 118 | 139 | 131 | 0 | 0 |
| Payable Days | 162 | 143 | 84 | 99 | 137 | 107 | 109 | 112 | 0 | 0 |
| 119 | 104 | 89 | 98 | 105 | 89 | 106 | 81 | 0 | 0 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 0.87x | 0.90x | 0.82x | 0.69x | 0.85x | 0.79x | 0.71x | 0.59x | 0.61x | 0.00x |
| Interest Coverage (x) | 1.57x | 1.54x | 1.40x | 1.30x | 0.24x | 1.43x | 0.53x | 1.20x | 1.13x | -1.34x |
| 1.17x | 1.27x | 1.28x | 1.29x | 1.04x | 1.35x | 1.38x | 1.32x | 1.21x | 9.71x | |
| GROWTH | ||||||||||
| Revenue Growth % | -1.91% | 14.15% | 48.32% | -14.97% | -34.78% | 8.13% | -8.70% | 10.53% | -100.00% | 0.00% |
| Operating Profit Growth % | 1.05% | -1.98% | 11.57% | -17.08% | -49.64% | 50.54% | -37.56% | 58.97% | -93.94% | -589.97% |
| Net Profit Growth % | 2.02% | -5.54% | -8.94% | -33.22% | -330.47% | 134.19% | -196.55% | 120.66% | -86.05% | -8327.69% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 120.66% | -2375.91% | -197.43% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 135.18x | 0.00x | 0.00x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.63x | 0.54x | 0.31x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 7.66x | 105.53x | -1.37x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-22 - Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.
2026-08-21 - Please find attached herewith newspaper publication of notice of 31st Annual General Meeting, e-voting, book closure & other information.
2026-08-20 - Nectar Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026
2026-08-20 - Please find attached herewith newspaper publication of notice to the shareholders regarding 31st AGM of the Company to be held on Friday, September 18, 2026, through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM), and other information as required under circulars issued by Ministry of Corporate Affairs
2026-08-15 - Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-15 - Nectar Lifesciences Limited has informed the Exchange about change in corporate office of the Company
2026-08-14 - Nectar Lifesciences Limited has informed the Exchange that Record date for the purpose of ascertaining the eligibility of members for remote e-voting and/ or polling/ e-voting at 31st AGM is 11-Sep-2026
2026-08-14 - We wish to inform you that the board of directors of Nectar Lifesciences Limited ( Company ) in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the following matters:1. Appointed Dr. Gunmala Suri (DIN: 11879344) as an Additional Director from August 15, 2026, till forthcoming Annual General meeting ( AGM ) as well as Non-Executive Non-Independent Director subject to approval of members at the forthcoming AGM of the Company with effect from August 15, 2026;2. To convene the 31st AGM of the members of the Company on Friday, September 18, 2026;3. To close the register of members and share transfer books from September 12, 2026, to September 18, 2026 (both days inclusive) for the purpose of AGM. Accordingly, the cut-off date, to ascertain the eligibility of members for remote e-voting and polling/ e-voting at AGM, is September 11, 2026, i.e., the date prior to the commencement of book closure;4. The re-appointment of Mr. Sanjiv Goyal (DIN: 00002841), director, who retire by rotation, in the forthcoming AGM;and5.. The proposal for appointment of Dr. Gunmala Suri (DIN: 11879344) as a regular director as well as Non-Executive Non-Independent Director with effect from August 15, 2026, subject to approval of the members at the forthcoming AGM.
2026-08-14 - Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
News
Recent coverage and analyst commentary for NECLIFE
Loading news…
AI Stock Analyst
Nectar Lifesciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account